Our Partners for Technical Cleanliness and Quality Assurance
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
OSB Representative Participant List by Industry
OSB Representative Participant List by Industry Aerospace • KAWASAKI • VOLVO • CATERPILLAR • ADVANCED COATING • KEDDEG COMPANY • XI'AN AIRCRAFT INDUSTRY • CHINA FAW GROUP TECHNOLOGIES GROUP • KOREAN AIRLINES • CHINA INTERNATIONAL Agriculture • AIRBUS MARINE CONTAINERS • L3 COMMUNICATIONS • AIRCELLE • AGRICOLA FORNACE • CHRYSLER • LOCKHEED MARTIN • ALLIANT TECHSYSTEMS • CARGILL • COMMERCIAL VEHICLE • M7 AEROSPACE GROUP • AVICHINA • E. RITTER & COMPANY • • MESSIER-BUGATTI- CONTINENTAL AIRLINES • BAE SYSTEMS • EXOPLAST DOWTY • CONTINENTAL • BE AEROSPACE • MITSUBISHI HEAVY • JOHN DEERE AUTOMOTIVE INDUSTRIES • • BELL HELICOPTER • MAUI PINEAPPLE CONTINENTAL • NASA COMPANY AUTOMOTIVE SYSTEMS • BOMBARDIER • • NGC INTEGRATED • USDA COOPER-STANDARD • CAE SYSTEMS AUTOMOTIVE Automotive • • CORNING • CESSNA AIRCRAFT NORTHROP GRUMMAN • AGCO • COMPANY • PRECISION CASTPARTS COSMA INDUSTRIAL DO • COBHAM CORP. • ALLIED SPECIALTY BRASIL • VEHICLES • CRP INDUSTRIES • COMAC RAYTHEON • AMSTED INDUSTRIES • • CUMMINS • DANAHER RAYTHEON E-SYSTEMS • ANHUI JIANGHUAI • • DAF TRUCKS • DASSAULT AVIATION RAYTHEON MISSLE AUTOMOBILE SYSTEMS COMPANY • • ARVINMERITOR DAIHATSU MOTOR • EATON • RAYTHEON NCS • • ASHOK LEYLAND DAIMLER • EMBRAER • RAYTHEON RMS • • ATC LOGISTICS & DALPHI METAL ESPANA • EUROPEAN AERONAUTIC • ROLLS-ROYCE DEFENCE AND SPACE ELECTRONICS • DANA HOLDING COMPANY • ROTORCRAFT • AUDI CORPORATION • FINMECCANICA ENTERPRISES • • AUTOZONE DANA INDÚSTRIAS • SAAB • FLIR SYSTEMS • • BAE SYSTEMS DELPHI • SMITH'S DETECTION • FUJI • • BECK/ARNLEY DENSO CORPORATION -
Retirement Strategy Fund 2060 Description Plan 3S DCP & JRA
Retirement Strategy Fund 2060 June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA ACTIVIA PROPERTIES INC REIT 0.0137% 0.0137% AEON REIT INVESTMENT CORP REIT 0.0195% 0.0195% ALEXANDER + BALDWIN INC REIT 0.0118% 0.0118% ALEXANDRIA REAL ESTATE EQUIT REIT USD.01 0.0585% 0.0585% ALLIANCEBERNSTEIN GOVT STIF SSC FUND 64BA AGIS 587 0.0329% 0.0329% ALLIED PROPERTIES REAL ESTAT REIT 0.0219% 0.0219% AMERICAN CAMPUS COMMUNITIES REIT USD.01 0.0277% 0.0277% AMERICAN HOMES 4 RENT A REIT USD.01 0.0396% 0.0396% AMERICOLD REALTY TRUST REIT USD.01 0.0427% 0.0427% ARMADA HOFFLER PROPERTIES IN REIT USD.01 0.0124% 0.0124% AROUNDTOWN SA COMMON STOCK EUR.01 0.0248% 0.0248% ASSURA PLC REIT GBP.1 0.0319% 0.0319% AUSTRALIAN DOLLAR 0.0061% 0.0061% AZRIELI GROUP LTD COMMON STOCK ILS.1 0.0101% 0.0101% BLUEROCK RESIDENTIAL GROWTH REIT USD.01 0.0102% 0.0102% BOSTON PROPERTIES INC REIT USD.01 0.0580% 0.0580% BRAZILIAN REAL 0.0000% 0.0000% BRIXMOR PROPERTY GROUP INC REIT USD.01 0.0418% 0.0418% CA IMMOBILIEN ANLAGEN AG COMMON STOCK 0.0191% 0.0191% CAMDEN PROPERTY TRUST REIT USD.01 0.0394% 0.0394% CANADIAN DOLLAR 0.0005% 0.0005% CAPITALAND COMMERCIAL TRUST REIT 0.0228% 0.0228% CIFI HOLDINGS GROUP CO LTD COMMON STOCK HKD.1 0.0105% 0.0105% CITY DEVELOPMENTS LTD COMMON STOCK 0.0129% 0.0129% CK ASSET HOLDINGS LTD COMMON STOCK HKD1.0 0.0378% 0.0378% COMFORIA RESIDENTIAL REIT IN REIT 0.0328% 0.0328% COUSINS PROPERTIES INC REIT USD1.0 0.0403% 0.0403% CUBESMART REIT USD.01 0.0359% 0.0359% DAIWA OFFICE INVESTMENT -
Media R Elease
Frankfurt/Main, 5 December 2018 Carl Zeiss Meditec AG to be included in MDAX Three changes in SDAX/ Changes to be effective as of 27 December 2018 On Wednesday, Deutsche Börse announced changes to its selection indices, which will become effective on 27 December 2018. The shares of Carl Zeiss Meditec AG will be included in the MDAX index and will replace the shares of CTS Eventim AG & CO. KGaA, which will be included in the SDAX index. The exclusion of CTS Eventim AG & CO. KGaA is based on the fast exit rule; Carl Zeiss Meditec AG is eligible for the index inclusion due to its market capitalisation and order book turnover. MDAX tracks the 60 largest and most liquid companies below DAX. The following changes will apply to SDAX: CTS Eventim AG & CO. KGaA, Knorr- Bremse AG and VARTA AG will be included. The shares of BayWa AG and DMG Mori AG will be deleted from the index, according to the fast exit rule. SDAX tracks the 70 next biggest and most actively traded companies after the MDAX. The constituents of the indices DAX and TecDAX remain unchanged. The next scheduled index review is 5 March 2019. DAX®, MDAX®, SDAX® and TecDAX® are registered trademarks of Deutsche Börse AG. Media Release About Deutsche Börse – Market Data + Services In the area of data, Deutsche Börse Group is one of the world’s leading service providers for the securities industry with products and services for issuers, investors, intermediaries, and data vendors. The Group’s portfolio covers the entire value chain in the financial business. -
Petition of the Procter & Gamble Company for Approval of Proposed Divestiture
PUBLIC RECORD VERSION UNITED STATES OF AMERICA BEFÖRE FEDERAL TRADE COMMISSION COMMISSIONERS: Deborah Platt Majoras, Chairman Pamela Jones Harbour Jon Leibowitz Wiliam E. Kovacic J. Thomas Rosch ) In the Matter of ) ) THEa corporation;PROCTER & GAMBLE COMPANY, ) ) ) Docket No. C-4151 and ) File No. 051-0115 ) THE GILLETTE COMPANY, ) a corporation., ) ) ) PETITION OF THE PROCTER & GAMBLE COMPANY FOR APPROVAL OF PROPOSED DIVESTITURE Pursuant to Section 2.41(f) of the Federal Trade Commission ("Commission" or "FTC") Rules of Practice and Procedure, 16 CF.R. § 2.41(f) (2005), and Paragraph II.A. of the final Decision and Order approved by the Commission in the above-captioned matter, The Procter & Gamble Company ("P&G") hereby fies this Petition for Approval of Proposed Divestitue ("Petition") requesting the Commission's approval of the divestitue of the APDO business, including Right Guard, Soft & Dri, Dry Idea, Natrel Plus, and Balance ("the APDO Assets") of The Gilette Company ("Gilette"), to The Dial Corporation ("Dial"), a subsidiar of Henkel KGaA ("Henkel"). .~ PUBLIC RECORD VERSION I. INTRODUCTION On September 23,2005, P&G and the Commission entered into an Agreement Containing Consent Orders, including an initial Decision and Order and an Order to Maintain Assets. On October 1,2005, pursuant to an Agreement and Plan of Merger between P&G and Gilette dated Januar 27, 2005, P&G completed its acquisition of Gilette. After a period of public comment, on December 15, 2005, the Commission issued its final Decision and Order , ("Order") (with minor changes) and Order to Maintain Assets (without changes) (collectively, the "Consent Agreement"). At the same time it reissued its Complaint (also without changes). -
Incoming Letter: QIAGEN N.V
WACHTELL, LIPTON , ROSEN & KATZ MARTIN LIPTON STEVEN A. COHEN 51 W E S T 52N D S T R E E T DAVID E. SHAPIRO SABASTIAN V. NILES HERBERT M. WACHTELL DEBORAH L. PAUL DAMIAN G. DIDDEN ALISON ZIESKE PREISS THEODORE N. MIRVIS DAVID C. KARP NEW YORK, N.Y. 1 0 0 1 9 - 6 1 5 0 IAN B OC Z K O TIJANA J. DVORNIC EDWARD D. HERLIHY RICHARD K. KIM MATTHEW M. GUEST JENNA E. LEVINE DANIEL A. NEFF JOSHUA R. CAMMAKER TELEPHONE: (212) 403 -1000 DAVID E. KAHAN RYAN A. McLEOD ANDREW R. BROWNSTEIN MARK GORDON DAVID K. LAM ANITHA REDDY MARC WOLINSKY JOSEPH D. LARSON FACSIMILE: (212) 403 -2000 BENJAMIN M. ROTH JOHN L. ROBINSON STEVEN A. ROSENBLUM JEANNEMARIE O’BRIEN JOSHUA A. FELTMAN JOHN R. SOBOLEWSKI JOHN F. SAVARESE WAYNE M. CARLIN GEORGE A. KATZ (1965 -1 9 8 9) ELAINE P. GOLIN STEVEN WINTER SCOTT K. CHARLES STEPHEN R. D iPRIMA JAMES H. FOGELSON (1967 - 1 9 91) EMI L A. KLEINHAUS EMILY D. JOHNSON JODI J. SCHWARTZ NICHOLAS G. DEMMO LEONARD M. ROSEN (1965 - 2 0 14 ) KARESSA L. CAIN JACOB A. KLING ADAM O. EMMERICH IGOR KIRMAN RONALD C. CHEN RAAJ S. NARAYAN RALPH M. LEVENE JONATHAN M. MOSES OF C O UN S EL GORDON S. MOODIE VIKTOR SAPEZHNIKOV RICHARD G. MASON T. EIKO STANGE DONGJU SONG MICHAEL J. SCHOBEL MARTIN J.E. ARMS ERIC S. ROBINSON DAVID M. SILK JOHN F. LYNCH BRADLEY R. WILSON ELINA TETELBAUM MICHAEL H. BYOWITZ PATRICIA A. ROBINSON* ROBIN PANOVKA WILLIAM SAVITT GRAHAM W. -
List of SARS-Cov-2 Diagnostic Test Kits and Equipments Eligible For
Version 33 2021-09-24 List of SARS-CoV-2 Diagnostic test kits and equipments eligible for procurement according to Board Decision on Additional Support for Country Responses to COVID-19 (GF/B42/EDP11) The following emergency procedures established by WHO and the Regulatory Authorities of the Founding Members of the GHTF have been identified by the QA Team and will be used to determine eligibility for procurement of COVID-19 diagnostics. The product, to be considered as eligible for procurement with GF resources, shall be listed in one of the below mentioned lists: - WHO Prequalification decisions made as per the Emergency Use Listing (EUL) procedure opened to candidate in vitro diagnostics (IVDs) to detect SARS-CoV-2; - The United States Food and Drug Administration’s (USFDA) general recommendations and procedures applicable to the authorization of the emergency use of certain medical products under sections 564, 564A, and 564B of the Federal Food, Drug, and Cosmetic Act; - The decisions taken based on the Canada’s Minister of Health interim order (IO) to expedite the review of these medical devices, including test kits used to diagnose COVID-19; - The COVID-19 diagnostic tests approved by the Therapeutic Goods Administration (TGA) for inclusion on the Australian Register of Therapeutic Goods (ARTG) on the basis of the Expedited TGA assessment - The COVID-19 diagnostic tests approved by the Ministry of Health, Labour and Welfare after March 2020 with prior scientific review by the PMDA - The COVID-19 diagnostic tests listed on the French -
Euro Stoxx® Multi Premia Index
EURO STOXX® MULTI PREMIA INDEX Components1 Company Supersector Country Weight (%) SARTORIUS STEDIM BIOTECH Health Care France 1.59 IMCD Chemicals Netherlands 1.25 VOPAK Industrial Goods & Services Netherlands 1.15 BIOMERIEUX Health Care France 1.04 REMY COINTREAU Food, Beverage & Tobacco France 1.03 EURONEXT Financial Services France 1.00 HERMES INTERNATIONAL Consumer Products & Services France 0.94 SUEZ ENVIRONNEMENT Utilities France 0.94 BRENNTAG Chemicals Germany 0.93 ENAGAS Energy Spain 0.90 ILIAD Telecommunications France 0.89 DEUTSCHE POST Industrial Goods & Services Germany 0.88 FUCHS PETROLUB PREF Chemicals Germany 0.88 SEB Consumer Products & Services France 0.87 SIGNIFY Construction & Materials Netherlands 0.86 CARL ZEISS MEDITEC Health Care Germany 0.80 SOFINA Financial Services Belgium 0.80 EUROFINS SCIENTIFIC Health Care France 0.80 RATIONAL Industrial Goods & Services Germany 0.80 AALBERTS Industrial Goods & Services Netherlands 0.74 KINGSPAN GRP Construction & Materials Ireland 0.73 GERRESHEIMER Health Care Germany 0.72 GLANBIA Food, Beverage & Tobacco Ireland 0.71 PUBLICIS GRP Media France 0.70 UNITED INTERNET Technology Germany 0.70 L'OREAL Consumer Products & Services France 0.70 KPN Telecommunications Netherlands 0.68 SARTORIUS PREF. Health Care Germany 0.68 BMW Automobiles & Parts Germany 0.68 VISCOFAN Food, Beverage & Tobacco Spain 0.67 SAINT GOBAIN Construction & Materials France 0.67 CORBION Food, Beverage & Tobacco Netherlands 0.66 DAIMLER Automobiles & Parts Germany 0.66 PROSIEBENSAT.1 MEDIA Media Germany 0.65 -
Weekly Screener 17 May – 24 May 2021, Week 20
AlsterResearch Weekly Screener Page 1 of 6 Weekly Screener 17 May – 24 May 2021, Week 20 Rotation Victims Target Find the stocks that have suffered most from sector rotation. Method Identify the beginning of the sector rotation as the yearly high of the Nasdaq in relation to the Dow Jones Industrial: 12th February 2021. Calculate the stock performance since then and select the companies with the biggest decline. Result from AlsterResearch universe: Rotation Victims Name Performance since start of sector rotation GICS Subsector TeamViewer AG -33,2% Application Software Varta AG -26,9% Electrical Components & Equipment CompuGroup Medical -20,2% Health Care Technology Delivery Hero SE -19,0% Internet & Direct Marketing Retail Formycon AG -18,8% Biotechnology MAKING SENSE OF THE NUMBERS: TeamViewer (AlsterResearch view: BUY / PT EUR 39 / closing price EUR 30,66 / upside 28%) The remote access specialist had to suffer twice: an ill-received marketing partnership with Manchester United AND the rotation out of tech both hurt. Attractive again at current levels. Varta (AlsterResearch view: BUY / PT EUR 130,00 / closing price EUR 116,00 / upside 12%) Varta is translating global market leadership in hearing aid and wireless headset batteries into substantial returns. Sector rotation and a sluggish Q1 could provide a good entry point. CompuGroup Medical (AlsterResearch view: BUY / PT EUR 72,00 / closing price EUR 63,55 / upside 13%) CompuGroup is a provider of software for the healthcare sector. The market currently has decided to treat it as “tech” and not as “health care” and rotate out, probably also as a result of weakish Q1 figures. -
FACTSHEET - AS of 28-Sep-2021 Solactive Mittelstand & Midcap Deutschland Index (TRN)
FACTSHEET - AS OF 28-Sep-2021 Solactive Mittelstand & MidCap Deutschland Index (TRN) DESCRIPTION The Index reflects the net total return performance of 70 medium/smaller capitalisation companies incorporated in Germany. Weights are based on free float market capitalisation and are increased if significant holdings in a company can be attributed to currentmgmtor company founders. HISTORICAL PERFORMANCE 350 300 250 200 150 100 50 Jan-2010 Jan-2012 Jan-2014 Jan-2016 Jan-2018 Jan-2020 Jan-2022 Solactive Mittelstand & MidCap Deutschland Index (TRN) CHARACTERISTICS ISIN / WKN DE000SLA1MN9 / SLA1MN Base Value / Base Date 100 Points / 19.09.2008 Bloomberg / Reuters MTTLSTRN Index / .MTTLSTRN Last Price 342.52 Index Calculator Solactive AG Dividends Included (Performance Index) Index Type Equity Calculation 08:00am to 06:00pm (CET), every 15 seconds Index Currency EUR History Available daily back to 19.09.2008 Index Members 70 FACTSHEET - AS OF 28-Sep-2021 Solactive Mittelstand & MidCap Deutschland Index (TRN) STATISTICS 30D 90D 180D 360D YTD Since Inception Performance -3.69% 3.12% 7.26% 27.72% 12.73% 242.52% Performance (p.a.) - - - - - 9.91% Volatility (p.a.) 13.05% 12.12% 12.48% 13.60% 12.90% 21.43% High 357.49 357.49 357.49 357.49 357.49 357.49 Low 342.52 329.86 315.93 251.01 305.77 52.12 Sharpe Ratio -2.77 1.14 1.27 2.11 1.40 0.49 Max. Drawdown -4.19% -4.19% -4.19% -9.62% -5.56% -47.88% VaR 95 \ 99 -21.5% \ -35.8% -34.5% \ -64.0% CVaR 95 \ 99 -31.5% \ -46.8% -53.5% \ -89.0% COMPOSITION BY CURRENCIES COMPOSITION BY COUNTRIES EUR 100.0% DE -
QIAGEN N.V. Annual Report 1999
13878_Cover99.qxd 26.05.2000 12:50 Uhr Seite 1 QIAGEN N.V. QIAGEN N.V. Annual Report 1999 Annual Report 1999 1013878 1013878_Cover99_Inside.qxd 26.05.2000 11:58 Uhr Seite 1 Contents QIAGEN Around the World 2 Report of the Supervisory Board 4 Letter from the Management Board Venlo 6 Fueling Momentum in the Biotech Industry London Düsseldorf Toronto Paris Basel 12 Building for the Future Valencia Tokyo 14 Contents — Financial Data QIAGEN is the world’s leading provider of innovative 1999 was a year of momentum for QIAGEN as our technologies for separating and purifying DNA and innovative technologies helped fuel the surge in RNA — the genetic blueprints of life. Since 1986, biotechnology. Building on our leading position in the QIAGEN has been successfully developing, producing, research market, we have created a wealth of new Melbourne and marketing an ever increasing range of proprietary opportunities in genomics, molecular diagnostics, and QIAGEN Companies products for academic, industrial, and clinical research. gene therapy markets through new innovative products QIAGEN Distributors and strategic alliances with key commercial players. At the dawn of the new century, the pace of genetic Our unique market position and tradition of innovation, discovery is accelerating at an unprecedented rate. quality, and service are generating exciting opportunities QIAGEN Contact Info New disease-associated genes are being identified which will fuel the Company’s continued momentum of almost daily, promising a future of targeted medical growth and success. The Netherlands Japan treatments based on genetic information and efficient QIAGEN N.V. QIAGEN K.K. management of infectious disease. -
EXTEL 2018 Investor Relations Rankings for Germany
EXTEL 2018 Investor Relations rankings for Germany June 2018 1. EXECUTIVE OVERVIEW & COMMENTARY This year marks the 13th Anniversary of the partnership between DIRK – Deutsche Investor Relations Verband - and Extel, an Institutional Investor Company. Every year, this successful collaboration produces the highly lauded Investor Relations Study, which takes its data from Extel’s comprehensive annual Pan-European Survey. The survey measures IR excellence and includes insightful views and trend information from investment professionals globally who are either invested in or cover the German equity market. The results of the study form the basis of the ‘Deutsche Investor Relations Preis’, presented during the DIRK annual conference in Frankfurt in June 2018. As part of its annual Pan-European Survey, year. The leading MDAX IR Professional Extel undertook this study from 14th March to was Burkhard Sawazki of LEG Immobilien 27th April, 2018; seeking ratings and rankings where 136 individuals received for IR excellence, at a company level and nominations. separately for IR professionals. From the In the SDAX category Hapag-Lloyd moved overall sector contributions, we derived up from 11th last year to 1st place. For the distinct rankings for the main German equity individual IR Professional ranking in SDAX, indices constituents – DAX30, MDAX, SDAX and Stephan Haas of SAF-HOLLAND was TecDAX. The study was undertaken almost ranked 1st, out of 61 individuals receiving exclusively through direct online votes. nominations. Telefonica Deutschland held on to top Since the beginning of the Extel and DIRK’s spot as the highly regarded TecDAX partnership in 2006, responses have increased company for IR. -
MFS® Research International Fund (Class R6 Shares) Second Quarter 2021 Investment Report
MFS® Research International Fund (Class R6 Shares) Second quarter 2021 investment report NOT FDIC INSURED MAY LOSE VALUE NOT A DEPOSIT Before investing, consider the fund's investment objectives, risks, charges, and expenses. For a prospectus, or summary prospectus, containing this and other information, contact MFS or view online at mfs.com. Please read it carefully. ©2021 MFS Fund Distributors, Inc., 111 Huntington Avenue, Boston, MA 02199. FOR DEALER AND INSTITUTIONAL USE ONLY. Not to be shown, quoted, or distributed to the public. PRPEQ-RIF-30-Jun-21 34135 Table of Contents Contents Page Fund Risks 1 Disciplined Investment Approach 2 Market Overview 3 Executive Summary 4 Performance 5 Attribution 6 Significant Transactions 10 Portfolio Positioning 11 Characteristics 13 Portfolio Outlook 14 Portfolio Holdings 18 Additional Disclosures 21 Country and region information contained in this report is based upon MFS classification methodology which may differ from the methodology used by individual benchmark providers. Performance and attribution results are for the fund or share class depicted and do not reflect the impact of your contributions and withdrawals. Your personal performance results may differ. Portfolio characteristics are based on equivalent exposure, which measures how a portfolio's value would change due to price changes in an asset held either directly or, in the case of a derivative contract, indirectly. The market value of the holding may differ. 0 FOR DEALER AND INSTITUTIONAL USE ONLY. - MFS Research International Fund PRPEQ-RIF-30-Jun-21 Fund Risks The fund may not achieve its objective and/or you could lose money on your investment in the fund.